On Sunday evening, Amman Pharmaceutical Industries held a ceremony to launch its new class “ClasGen” with a formulation of cyclosporine in the form of a single-dose sample drop, as this formulation is the only proven treatment by the US Food and Drug Administration (FDA) for the treatment of Dry Eye Syndrome.
The new drug class joined the group of other brands amounting to 170 registered preparations, which the company produces in its factory.
Where the ceremony was held in the presence of a large group of ophthalmologists in Jordan, and included a scientific lecture to raise awareness of the uses of the new treatment given by Dr. Khaled Ayesh, a consultant ophthalmologist in Jordan, and Dr. Fadi Al-Atrash, CEO and member of the Board of Directors of Amman Pharmaceutical Industries, gave a speech about the latest findings. The company is one of the achievements and technological developments in the field of pharmaceutical industries and the arrival of some of the company’s products to the American market.
Amman Pharmaceutical Industries (API) was established in 1989 as one of the first pharmaceutical companies in the MENA region to pioneer the production of niche branded generics in the therapeutic areas of Ophthalmology, ENT (Ear, Nose & Throat ) , respiratory, and Dermatology. After many years of success.
